CDKN2A and neoplasm: Importantly, we observed that TYMS cooperates with heterozygote Ink4a/Arf inactivation increasing the underlying tumor incidence and decreasing survival of hTS/Ink4a/Arf+/- mice that otherwise show indolent tumors with a long latency.